Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.55 |
| ▸ | LOX | P28300 | 5/20 | 0.55 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17372124 | 0.98 | LOXL2 (0.53) | LOXL2LOXLOXL3RECQLROCK1 | |
| SCHEMBL13541414 | 0.84 | RECQL (0.61) | LOXL2LOXLOXL3RECQLENPP2 | |
| SCHEMBL4107151 | 0.84 | LOXL2 (0.61) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL2642380 | 0.83 | RECQL (0.55) | LOXL2LOXLOXL3RECQL | |
| Hydrochloric Acid SCHEMBL5013442 | 0.82 | LOXL2 (0.59) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL1654460 | 0.78 | LOXL2 (0.55) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL5115940 | 0.78 | NOS3 (0.55) | RECQL | |
| SCHEMBL1387805 | 0.78 | RECQL (0.45) | LOXL2LOXLOXL3RECQL | |
| SCHEMBL17018998 | 0.78 | RECQL (0.45) | LOXL2LOXLOXL3RECQL | |
| SCHEMBL9253968 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4476207-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-0189678-B1 | ELECTROCHEMICAL REDUCTIONS OF PYRIDINE CARBOXAMIDE BASES | REILLY INDUSTRIES, INC. (US) | 1991-11-06 | — | — | EP | disclosed |
| US-4695352-A | Electrochemical reduction of pyridine carboxamide bases | REILLY TAR & CHEMICAL CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| US-4607107-A | CHEMICAL INTERMEDIATES FOR HESTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1986-08-19 | — | — | US | disclosed |
| EP-0189678-A1 | Electrochemical reductions of pyridine carboxamide bases | REILLY INDUSTRIES, INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| EP-0049173-B1 | PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL DERIVATIVES CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-03 | — | — | EP | disclosed |
| US-4439609-A | 4-TERT-AMINOALKYL, 2-AMINOALKOXY OR 2-AMINOALKYLENETHIOALKYL SUBSTITUTED, CHEMICAL INTERMEDIATES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-03-27 | — | — | US | disclosed |
| US-4385058-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0049173-A2 | Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | LOXL2 72/4885LOX 1570/4885LOXL3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.